The most common CD molecules mentioned in the publications included in this review of breast and pancreatic cancers were CD4 and CD8, in the context of treatment (53, 55, 91); while others such as CD19 and CD16 were also assessed in several studies, both for treatment as well (85). Here, CD19 is linked to familial pancreatic carcinoma.